Verona pharma to present additional analysis of phase 3 enhance-1 study in copd at ers international congress 2023

Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of pde3 and pde4 substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of pde3 and pde4
VRNA Ratings Summary
VRNA Quant Ranking